Genelux Corporation (GNLX)
Largest Insider Buys in Sector
GNLX Stock Price History Chart
GNLX Stock Performance
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated …
Insider Activity of Genelux Corporation
Over the last 12 months, insiders at Genelux Corporation have bought $1.07M and sold $2.12M worth of Genelux Corporation stock.
On average, over the past 5 years, insiders at Genelux Corporation have bought $536,625 and sold $8.12M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Zindrick Thomas (President and CEO) — $800,000. Zak Lourie S. (Chief Financial Officer) — $125,000. Tyree James L (director) — $100,000.
The last purchase of 2,500 shares for transaction amount of $10,000 was made by Yu Yong (VP, Clinical Trial Operations) on 2024‑05‑29.
List of Insider Buy and Sell Transactions, Genelux Corporation
| 2024-12-16 | Sale | Chief Financial Officer | 2,103 0.0061% | $2.34 | $4,921 | -2.54% | ||
| 2024-12-16 | Sale | President and CEO | 14,315 0.0416% | $2.34 | $33,497 | -2.54% | ||
| 2024-12-16 | Sale | Head of Regulatory | 2,510 0.0073% | $2.34 | $5,873 | -2.54% | ||
| 2024-12-16 | Sale | VP, Pharmaceutical Development | 6,300 0.0183% | $2.34 | $14,742 | -2.54% | ||
| 2024-09-13 | Sale | 10 percent owner | 33,080 0.1008% | $2.57 | $84,946 | +7.17% | ||
| 2024-09-12 | Sale | 10 percent owner | 31,777 0.0941% | $2.73 | $86,732 | -2.25% | ||
| 2024-09-11 | Sale | 10 percent owner | 31,376 0.0949% | $2.62 | $82,227 | +1.88% | ||
| 2024-09-11 | Sale | director | 1,730 0.0052% | $2.60 | $4,499 | +2.67% | ||
| 2024-09-10 | Sale | 10 percent owner | 20,384 0.059% | $2.51 | $51,182 | +4.18% | ||
| 2024-09-09 | Sale | 10 percent owner | 23,383 0.0678% | $2.70 | $63,200 | -3.33% | ||
| 2024-09-03 | Sale | 10 percent owner | 42,818 0.1248% | $2.09 | $89,614 | +25.96% | ||
| 2024-08-30 | Sale | 10 percent owner | 142,589 0.4134% | $2.17 | $309,846 | +20.51% | ||
| 2024-08-29 | Sale | 10 percent owner | 107,045 0.31% | $1.98 | $211,960 | +31.82% | ||
| 2024-08-28 | Sale | 10 percent owner | 15,918 0.0477% | $2.05 | $32,605 | +31.31% | ||
| 2024-08-27 | Sale | 10 percent owner | 51,630 0.1508% | $2.11 | $108,862 | +23.92% | ||
| 2024-08-23 | Sale | 10 percent owner | 40,000 0.1171% | $2.29 | $91,416 | +13.27% | ||
| 2024-06-24 | Sale | General Counsel | 5,496 0.0149% | $2.12 | $11,652 | +8.55% | ||
| 2024-06-24 | Sale | Head of Quality | 4,961 0.0134% | $2.12 | $10,517 | +8.55% | ||
| 2024-06-24 | Sale | VP, Clinical Trial Operations | 6,849 0.0185% | $2.12 | $14,520 | +8.55% | ||
| 2024-05-29 | director | 2,500 0.0105% | $4.00 | $10,000 | -12.50% |
Insider Historical Profitability
| Thomas John | director | 465960 1.3491% | $2.44 | 1 | 4 | |
| Tyree James L | director | 47521 0.1376% | $2.44 | 1 | 2 | |
| Zak Lourie S. | Chief Financial Officer | 40802 0.1181% | $2.44 | 1 | 1 | |
| Zindrick Thomas | President and CEO | 37372 0.1082% | $2.44 | 1 | 2 | |
| Ryder Sean | General Counsel | 19388 0.0561% | $2.44 | 1 | 3 |
Institutional Investor Ownership
| BlackRock | $7.92M | 3.59 | 1.23M | -5.03% | -$419,364.59 | <0.0001 | |
| Woodward Diversified Capital Llc | $6.98M | 3.16 | 1.09M | +0.34% | +$23,707.41 | 4.38 | |
| The Vanguard Group | $6.58M | 2.98 | 1.02M | +2.42% | +$155,734.60 | <0.0001 | |
| Geode Capital Management | $2.73M | 1.24 | 424,265 | +4.7% | +$122,537.98 | <0.0001 | |
| State Street | $2.54M | 1.15 | 395,015 | +4.66% | +$112,987.94 | <0.0001 |